For following the competition: what moved in each program, several studies read as one move.
- zanzalintinib
- cabozantinib
- Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628
- + 1 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Exelixis to watchlistEvery Monday by email · turn it off any timePro · free during the beta